Antibody-targeted drugs and drug resistance - Challenges and solutions

Drug Resistance Updates

Volumn 18, Issue , 2015, Pages 36-46

  Shefet Carasso, Leeron ^a   Benhar, Itai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adcetris Antibody drug ratio (ADR); Antibody drug conjugates (ADCs); Cancer; Kadcyla; Linker; Monoclonal antibodies (mAbs); Multidrug resistance (MDR); Mylotarg; Targeted therapeutics

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; COLTUXIMAB RAVTANSINE; CYTOTOXIC AGENT; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; INOTUZUMAB OZOGAMICIN; LABETUZUMAB; LORVOTUZUMAB MERTANSINE; MILATUZUMAB; MULTIDRUG RESISTANCE PROTEIN 1; PINATUZUMAB VEDOTIN; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; DRUG DESIGN; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 84922269141     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2014.11.001     Document Type: Article

References (168)

1. J.R. Adair, P.W. Howard, J.A. Hartley, D.G. Williams, and K.A. Chester Antibody-drug conjugates - a perfect synergy Expert Opin. Biol. Ther. 12 2012 1191 1206
2. R.F. Alderson, R.J. Kreitman, T. Chen, P. Yeung, R. Herbst, J.A. Fox, and I. Pastan CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies Clin. Cancer Res. 15 2009 832 839
3. S.C. Alley, D.R. Benjamin, S.C. Jeffrey, N.M. Okeley, D.L. Meyer, R.J. Sanderson, and P.D. Senter Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjug. Chem. 19 2008 759 765
4. S.C. Alley, N.M. Okeley, and P.D. Senter Antibody-drug conjugates: targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14 2010 529 537
5. S.C. Alley, X. Zhang, N.M. Okeley, M. Anderson, C.L. Law, P.D. Senter, and D.R. Benjamin The pharmacologic basis for antibody-auristatin conjugate activity J. Pharmacol. Exp. Ther. 330 2009 932 938
6. S.M. Ansell Brentuximab vedot delivering an antimitotic drug to activated lymphoma cells Expert Opin. Investig. Drugs 20 2011 99 105
7. E. Apostolidou, J. Cortes, A. Tsimberidou, E. Estey, H. Kantarjian, and F.J. Giles Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia Leuk. Res. 27 2003 887 891
8. J. Arribas, J. Baselga, K. Pedersen, and J.L. Parra-Palau p95HER2 and breast cancer Cancer Res. 71 2011 1515 1519
9. C.D. Austin, A.M. De Maziere, P.I. Pisacane, S.M. van Dijk, C. Eigenbrot, M.X. Sliwkowski, J. Klumperman, and R.H. Scheller Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin Mol. Biol. Cell 15 2004 5268 5282
10. J.Y. Axup, K.M. Bajjuri, M. Ritland, B.M. Hutchins, C.H. Kim, S.A. Kazane, R. Halder, J.S. Forsyth, A.F. Santidrian, K. Stafin, Y. Lu, H. Tran, A.J. Seller, S.L. Biroc, A. Szydlik, J.K. Pinkstaff, F. Tian, S.C. Sinha, B. Felding-Habermann, V.V. Smider, and P.G. Schultz Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U. S. A. 109 2012 16101 16106
11. P.G. Baraldi, A. Bovero, F. Fruttarolo, D. Preti, M.A. Tabrizi, M.G. Pavani, and R. Romagnoli DNA minor groove binders as potential antitumor and antimicrobial agents Med. Res. Rev. 24 2004 475 528
12. M. Barok, H. Joensuu, and J. Isola Trastuzumab emtansine: mechanisms of action and drug resistance Breast Cancer Res. 16 2014 209
13. M. Barok, M. Tanner, K. Koninki, and J. Isola Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo Breast Cancer Res. 13 2011 R46
14. K.L. Blackwell, H.J. Burstein, A.M. Storniolo, H.S. Rugo, G. Sledge, G. Aktan, C. Ellis, A. Florance, S. Vukelja, J. Bischoff, J. Baselga, and J. O'Shaughnessy Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study J. Clin. Oncol. 30 2012 2585 2592
15. D.L. Boger, and D.S. Johnson CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents Proc. Natl. Acad. Sci. U. S. A. 92 1995 3642 3649
16. E.R. Boghaert, K.M. Khandke, L. Sridharan, M. Dougher, J.F. DiJoseph, A. Kunz, P.R. Hamann, J. Moran, I. Chaudhary, and N.K. Damle Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples Cancer Chemother. Pharmacol. 61 2008 1027 1035
17. N.J. Boylan, W. Zhou, R.J. Proos, T.J. Tolbert, J.L. Wolfe, and J.S. Laurence Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates Bioconjug. Chem. 24 2013 1008 1016
18. M. Breccia, and F. Lo-Coco Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy Expert Opin. Biol. Ther. 11 2011 225 234
19. P.F. Bross, J. Beitz, G. Chen, X.H. Chen, E. Duffy, L. Kieffer, S. Roy, R. Sridhara, A. Rahman, G. Williams, and R. Pazdur Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin. Cancer Res. 7 2001 1490 1496
20. J.M. Burke, J.G. Jurcic, and D.A. Scheinberg Radioimmunotherapy for acute leukemia Cancer Control: J. Moffitt Cancer Center 9 2002 106 113
21. P.J. Burke, P.D. Senter, D.W. Meyer, J.B. Miyamoto, M. Anderson, B.E. Toki, G. Manikumar, M.C. Wani, D.J. Kroll, and S.C. Jeffrey Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues Bioconjug. Chem. 20 2009 1242 1250
22. H.A. Burris 3rd, H.S. Rugo, S.J. Vukelja, C.L. Vogel, R.A. Borson, S. Limentani, E. Tan-Chiu, I.E. Krop, R.A. Michaelson, S. Girish, L. Amler, M. Zheng, Y.W. Chu, B. Klencke, and J.A. O'Shaughnessy Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy J. Clin. Oncol. 29 2011 398 405
23. F. Cabral, M.E. Sobel, and M.M. Gottesman CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered beta-tubulin Cell 20 1980 29 36
24. P.C. Caron, M.S. Co, M.K. Bull, N.M. Avdalovic, C. Queen, and D.A. Scheinberg Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies Cancer Res. 52 1992 6761 6767
25. P. Carter Improving the efficacy of antibody-based cancer therapies Nat. Rev. Cancer 1 2001 118 129
26. P.J. Carter, and P.D. Senter Antibody-drug conjugates for cancer therapy Cancer J. 14 2008 154 169
27. G. Casi, and D. Neri Antibody-drug conjugates: basic concepts, examples and future perspectives J. Control. Release 161 2012 422 428
28. R.V. Chari Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy Adv. Drug Deliv. Rev. 31 1998 89 104
29. R.V. Chari Targeted cancer therapy: conferring specificity to cytotoxic drugs Acc. Chem. Res. 41 2008 98 107
30. R.V. Chari, B.A. Martell, J.L. Gross, S.B. Cook, S.A. Shah, W.A. Blattler, S.J. McKenzie, and V.S. Goldmacher Immunoconjugates containing novel maytansinoids: promising anticancer drugs Cancer Res. 52 1992 127 131
31. B.D. Cheson, and J.P. Leonard Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma N. Engl. J. Med. 359 2008 613 626
32. M. Cianfriglia, A. Mallano, A. Ascione, and M.L. Dupuis Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line Int. J. Oncol. 36 2010 1513 1520
33. P.M. Deckert Current constructs and targets in clinical development for antibody-based cancer therapy Curr. Drug Targets 10 2009 158 175
34. D. Dornan, F. Bennett, Y. Chen, M. Dennis, D. Eaton, K. Elkins, D. French, M.A. Go, A. Jack, J.R. Junutula, H. Koeppen, J. Lau, J. McBride, A. Rawstron, X. Shi, N. Yu, S.F. Yu, P. Yue, B. Zheng, A. Ebens, and A.G. Polson Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma Blood 114 2009 2721 2729
35. S.O. Doronina, B.A. Mendelsohn, T.D. Bovee, C.G. Cerveny, S.C. Alley, D.L. Meyer, E. Oflazoglu, B.E. Toki, R.J. Sanderson, R.F. Zabinski, A.F. Wahl, and P.D. Senter Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity Bioconjug. Chem. 17 2006 114 124
36. S.O. Doronina, B.E. Toki, M.Y. Torgov, B.A. Mendelsohn, C.G. Cerveny, D.F. Chace, R.L. DeBlanc, R.P. Gearing, T.D. Bovee, C.B. Siegall, J.A. Francisco, A.F. Wahl, D.L. Meyer, and P.D. Senter Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21 2003 778 784
37. P.M. Drake, and D. Rabuka Antibody-drug conjugates: can coupling cytotoxicity and specificity overcome therapeutic resistance? B. Bonavida, Resistance to Immunotherapeutic Antibodies in Cancer, Resistance to Targeted Anti-Cancer Therapeutics 2 2013 Springer Science+Business Media New York
38. G.M. Dubowchik, and R.A. Firestone Cathepsin B-sensitive dipeptide prodrugs 1. A model study of structural requirements for efficient release of doxorubicin Bioorg. Med. Chem. Lett. 8 1998 3341 3346
39. G.M. Dubowchik, R.A. Firestone, L. Padilla, D. Willner, S.J. Hofstead, K. Mosure, J.O. Knipe, S.J. Lasch, and P.A. Trail Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity Bioconjug. Chem. 13 2002 855 869
40. L. Ducry, and B. Stump Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies Bioconjug. Chem. 21 2010 5 13
41. P. Ehrlich The relationship existing between chemical constitution distribution and pharmacological action Collected Studies on Immunity 1906 Wiley & Sons 441 450
42. P. Ehrlich Chemotherapy F. Himmelwiet, Proceedings of 17th International Congress of medicine, Collected Papers of Paul Ehrlich 1913 Pergamon Press 505 518
43. P. Ehrlich Immunology and Cancer Research E. Himmelweit, The Collected Papers of Paul Ehrlich Vol. I Histology, Biochemistry and Pathology 1956 Pergamon London 442 447
44. H.K. Erickson, P.U. Park, W.C. Widdison, Y.V. Kovtun, L.M. Garrett, K. Hoffman, R.J. Lutz, V.S. Goldmacher, and W.A. Blattler Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res. 66 2006 4426 4433
45. H.K. Erickson, W.C. Widdison, M.F. Mayo, K. Whiteman, C. Audette, S.D. Wilhelm, and R. Singh Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates Bioconjug. Chem. 21 2010 84 92
46. J.A. Flygare, T.H. Pillow, and P. Aristoff Antibody-drug conjugates for the treatment of cancer Chem. Biol. Drug Des. 81 2013 113 121
47. M.M. Gottesman, I. Pastan, and S.V. Ambudkar P-glycoprotein and multidrug resistance Curr. Opin. Genet. Dev. 6 1996 610 617
48. P. Haag, K. Viktorsson, M.L. Lindberg, L. Kanter, R. Lewensohn, and L. Stenke Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML Exp. Hematol. 37 2009 755 766
49. P.R. Hamann, L.M. Hinman, C.F. Beyer, L.M. Greenberger, C. Lin, D. Lindh, A.T. Menendez, R. Wallace, F.E. Durr, and J. Upeslacis An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance Bioconjug. Chem. 16 2005 346 353
50. P.R. Hamann, L.M. Hinman, I. Hollander, C.F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H.R. Tsou, J. Upeslacis, D. Shochat, A. Mountain, D.A. Flowers, and I. Bernstein Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjug. Chem. 13 2002 47 58
51. K.J. Hamblett, P.D. Senter, D.F. Chace, M.M. Sun, J. Lenox, C.G. Cerveny, K.M. Kissler, S.X. Bernhardt, A.K. Kopcha, R.F. Zabinski, D.L. Meyer, and J.A. Francisco Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10 2004 7063 7070
52. J.A. Hartley The development of pyrrolobenzodiazepines as antitumour agents Expert Opin. Investig. Drugs 20 2011 733 744
53. J.A. Hartley, A. Hamaguchi, M. Suggitt, S.J. Gregson, D.E. Thurston, and P.W. Howard DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057 Invest. New Drugs 30 2012 950 958
54. A.A. Hertler, and A.E. Frankel Immunotoxins: a clinical review of their use in the treatment of malignancies J. Clin. Oncol. 7 1989 1932 1942
55. L.M. Hinman, P.R. Hamann, R. Wallace, A.T. Menendez, F.E. Durr, and J. Upeslacis Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics Cancer Res. 53 1993 3336 3342
56. J. Huober, P.A. Fasching, M. Barsoum, L. Petruzelka, D. Wallwiener, C. Thomssen, T. Reimer, S. Paepke, H.A. Azim, V. Ragosch, E. Kubista, A.K. Baumgartner, M.W. Beckmann, C. May, I. Nimmrich, and N. Harbeck Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial Breast 21 2012 27 33
57. S.A. Hurvitz, L. Dirix, J. Kocsis, G.V. Bianchi, J. Lu, J. Vinholes, E. Guardino, C. Song, B. Tong, V. Ng, Y.W. Chu, and E.A. Perez Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J. Clin. Oncol. 31 2013 1157 1163
58. M.L. Hutter, and R.F. Schlenk Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia Expert Opin. Biol. Ther. 11 2011 1369 1380
59. S. Jaracz, J. Chen, L.V. Kuznetsova, and I. Ojima Recent advances in tumor-targeting anticancer drug conjugates Bioorg. Med. Chem. 13 2005 5043 5054
60. I. Jedema, R.M. Barge, V.H. van der Velden, B.A. Nijmeijer, J.J. van Dongen, R. Willemze, and J.H. Falkenburg Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamic, rationale for efficacy in CD33-negative malignancies with endocytic capacity Leukemia 18 2004 316 325
61. S.C. Jeffrey, J.B. Andreyka, S.X. Bernhardt, K.M. Kissler, T. Kline, J.S. Lenox, R.F. Moser, M.T. Nguyen, N.M. Okeley, I.J. Stone, X. Zhang, and P.D. Senter Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates Bioconjug. Chem. 17 2006 831 840
62. S.C. Jeffrey, M.T. Nguyen, R.F. Moser, D.L. Meyer, J.B. Miyamoto, and P.D. Senter Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker Bioorg. Med. Chem. Lett. 17 2007 2278 2280
63. S.C. Jeffrey, M.Y. Torgov, J.B. Andreyka, L. Boddington, C.G. Cerveny, W.A. Denny, K.A. Gordon, D. Gustin, J. Haugen, T. Kline, M.T. Nguyen, and P.D. Senter Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates J. Med. Chem. 48 2005 1344 1358
64. W. Jin, J.D. Trzupek, T.J. Rayl, M.A. Broward, G.A. Vielhauer, S.J. Weir, I. Hwang, and D.L. Boger A unique class of duocarmycin and CC-1065 analogues subject to reductive activation J. Am. Chem. Soc. 129 2007 15391 15397
65. T.T. Junttila, K. Parsons, C. Olsson, Y. Lu, Y. Xin, J. Theriault, L. Crocker, O. Pabonan, T. Baginski, G. Meng, K. Totpal, R.F. Kelley, and M.X. Sliwkowski Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer Cancer Res. 70 2010 4481 4489
66. J.R. Junutula, S. Bhakta, H. Raab, K.E. Ervin, C. Eigenbrot, R. Vandlen, R.H. Scheller, and H.B. Lowman Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs J. Immunol. Methods 332 2008 41 52
67. J.R. Junutula, H. Raab, S. Clark, S. Bhakta, D.D. Leipold, S. Weir, Y. Chen, M. Simpson, S.P. Tsai, M.S. Dennis, Y. Lu, Y.G. Meng, C. Ng, J. Yang, C.C. Lee, E. Duenas, J. Gorrell, V. Katta, A. Kim, K. McDorman, K. Flagella, R. Venook, S. Ross, S.D. Spencer, W. Lee Wong, H.B. Lowman, R. Vandlen, M.X. Sliwkowski, R.H. Scheller, P. Polakis, and W. Mallet Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26 2008 925 932
68. N. Kartner, D. Evernden-Porelle, G. Bradley, and V. Ling Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies Nature 316 1985 820 823
69. F.H. Kasten Paul Ehrlich: pathfinder in cell biology. 1. Chronicle of his life and accomplishments in immunology, cancer research, and chemotherapy Biotech. Histochem. 71 1996 2 37
70. J. Katz, J.E. Janik, and A. Younes Brentuximab vedotin (SGN-35) Clin. Cancer Res. 17 2011 6428 6436
71. B. Kaufman, J.R. Mackey, M.R. Clemens, P.P. Bapsy, A. Vaid, A. Wardley, S. Tjulandin, M. Jahn, M. Lehle, A. Feyereislova, C. Revil, and A. Jones Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J. Clin. Oncol. 27 2009 5529 5537
72. M. Kavallaris Microtubules and resistance to tubulin-binding agents Nat. Rev. Cancer 10 2010 194 204
73. W.J. Kell, A.K. Burnett, R. Chopra, J.A. Yin, R.E. Clark, A. Rohatiner, D. Culligan, A. Hunter, A.G. Prentice, and D.W. Milligan A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia Blood 102 2003 4277 4283
74. B.A. Kellogg, L. Garrett, Y. Kovtun, K.C. Lai, B. Leece, M. Miller, G. Payne, R. Steeves, K.R. Whiteman, W. Widdison, H. Xie, R. Singh, R.V. Chari, J.M. Lambert, and R.J. Lutz Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage Bioconjug. Chem. 22 2011 717 727
75. A. Khandelwal, H. Saber, M.A. Shapiro, and H. Zhao Antibody-drug conjugate development L.P. GD, Antibody-drug Conjugates and Immunotoxins From Pre- Clinical Development to Therapeutic Application 2013 Humana Press New York 23 40
76. J. Kigawa, Y. Minagawa, Y. Kanamori, H. Itamochi, X. Cheng, M. Okada, T. Oishi, and N. Terakawa Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer Cancer 82 1998 697 702
77. I. Klein, B. Sarkadi, and A. Varadi An inventory of the human ABC proteins Biochim. Biophys. Acta 1461 1999 237 262
78. G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
79. E. Komlodi-Pasztor, D. Sackett, J. Wilkerson, and T. Fojo Mitosis is not a key target of microtubule agents in patient tumors Nat. Rev. Clin. Oncol. 8 2011 244 250
80. Y.V. Kovtun, C.A. Audette, M.F. Mayo, G.E. Jones, H. Doherty, E.K. Maloney, H.K. Erickson, X. Sun, S. Wilhelm, O. Ab, K.C. Lai, W.C. Widdison, B. Kellogg, H. Johnson, J. Pinkas, R.J. Lutz, R. Singh, V.S. Goldmacher, and R.V. Chari Antibody-maytansinoid conjugates designed to bypass multidrug resistance Cancer Res. 70 2010 2528 2537
81. Y.V. Kovtun, and V.S. Goldmacher Cell killing by Antibody-drug conjugates Cancer Lett. 255 2007 232 240
82. T.J. Kruser, and D.L. Wheeler Mechanisms of resistance to HER family targeting antibodies Exp. Cell Res. 316 2010 1083 1100
83. M.S. Kung Sutherland, R.B. Walter, S.C. Jeffrey, P.J. Burke, C. Yu, H. Kostner, I. Stone, M.C. Ryan, D. Sussman, R.P. Lyon, W. Zeng, K.H. Harrington, K. Klussman, L. Westendorf, D. Meyer, I.D. Bernstein, P.D. Senter, D.R. Benjamin, J.G. Drachman, and J.A. McEarchern SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML Blood 122 2013 1455 1463
84. R.A. Larson, M. Boogaerts, E. Estey, C. Karanes, E.A. Stadtmauer, E.L. Sievers, P. Mineur, J.M. Bennett, M.S. Berger, C.B. Eten, M. Munteanu, M.R. Loken, J.J. Van Dongen, I.D. Bernstein, F.R. Appelbaum, and G. Mylotarg Study Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) Leukemia 16 2002 1627 16136
85. G.A. Lazar, W. Dang, S. Karki, O. Vafa, J.S. Peng, L. Hyun, C. Chan, H.S. Chung, A. Eivazi, S.C. Yoder, J. Vielmetter, D.F. Carmichael, R.J. Hayes, and B.I. Dahiyat Engineered antibody Fc variants with enhanced effector function Proc. Natl. Acad. Sci. U. S. A. 103 2006 4005 4010
86. O. Legrand, R. Zittoun, and J.P. Marie Role of MRP1 in multidrug resistance in acute myeloid leukemia Leukemia 13 1999 578 584
87. G.D. Lewis Phillips, G. Li, D.L. Dugger, L.M. Crocker, K.L. Parsons, E. Mai, W.A. Blattler, J.M. Lambert, R.V. Chari, R.J. Lutz, W.L. Wong, F.S. Jacobson, H. Koeppen, R.H. Schwall, S.R. Kenkare-Mitra, S.D. Spencer, and M.X. Sliwkowski Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68 2008 9280 9290
88. M.L. Linenberger, T. Hong, D. Flowers, E.L. Sievers, T.A. Gooley, J.M. Bennett, M.S. Berger, L.H. Leopold, F.R. Appelbaum, and I.D. Bernstein Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Blood 98 2001 988 994
89. P. LoRusso, I.E. Krop, H.A.I. Burris, S.J. Vukelja, K. Miller, M. Zheng, Y. Chu, M. Lu, L.C. Amler, and H.S. Rugo Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy [abstract 1016] J. Clin. Oncol. 28 2010 15
90. P.M. LoRusso, D. Weiss, E. Guardino, S. Girish, and M.X. Sliwkowski Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer Clin. Cancer Res. 17 2011 6437 6447
91. B. Lowenberg, J.R. Downing, and A. Burnett Acute myeloid leukemia N. Engl. J. Med. 341 1999 1051 1062
92. A. Lyons, D.J. King, R.J. Owens, G.T. Yarranton, A. Millican, N.R. Whittle, and J.R. Adair Site-specific attachment to recombinant antibodies via introduced surface cysteine residues Protein Eng. 3 1990 703 708
93. W. Mao, E. Luis, S. Ross, J. Silva, C. Tan, C. Crowley, C. Chui, G. Franz, P. Senter, H. Koeppen, and P. Polakis EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer Cancer Res. 64 2004 781 788
94. M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, A. Lluch, J. Kennedy, K. O'Byrne, P. Conte, M. Green, C. Ward, K. Mayne, and J.M. Extra Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J. Clin. Oncol. 23 2005 4265 4274
95. D.Y. Mason, H. Stein, J. Gerdes, K.A. Pulford, E. Ralfkiaer, B. Falini, W.N. Erber, K. Micklem, and K.C. Gatter Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells Blood 69 1987 836 840
96. H. Matsui, A. Takeshita, K. Naito, K. Shinjo, K. Shigeno, M. Maekawa, Y. Yamakawa, M. Tanimoto, M. Kobayashi, K. Ohnishi, and R. Ohno Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers Leukemia 16 2002 813 819
97. T. Matsumoto, S. Jimi, S. Hara, Y. Takamatsu, J. Suzumiya, and K. Tamura Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin Leuk. Lymph. 53 2012 1399 1405
98. C.F. McDonagh, E. Turcott, L. Westendorf, J.B. Webster, S.C. Alley, K. Kim, J. Andreyka, I. Stone, K.J. Hamblett, J.A. Francisco, and P. Carter Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng. Des. Sel. 19 2006 299 307
99. G. Moldenhauer, A.V. Salnikov, S. Luttgau, I. Herr, J. Anderl, and H. Faulstich Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma J. Natl. Cancer Inst. 104 2012 622 634
100. J. Moore, K. Seiter, J. Kolitz, W. Stock, F. Giles, M. Kalaycio, D. Zenk, and G. Marcucci A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse Leuk. Res. 30 2006 777 783
101. A. Mullard Maturing antibody-drug conjugate pipeline hits 30 Nat. Rev. Drug Discov. 12 2013 329 332
102. P. Nagy, E. Friedlander, M. Tanner, A.I. Kapanen, K.L. Carraway, J. Isola, and T.M. Jovin Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line Cancer Res. 65 2005 473 482
103. K. Naito, A. Takeshita, K. Shigeno, S. Nakamura, S. Fujisawa, K. Shinjo, H. Yoshida, K. Ohnishi, M. Mori, S. Terakawa, and R. Ohno Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines Leukemia 14 2000 1436 1443
104. S. Nobili, I. Landini, T. Mazzei, and E. Mini Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression Med. Res. Rev. 32 2012 1220 1262
105. C. O'Brien, G. Cavet, A. Pandita, X. Hu, L. Haydu, S. Mohan, K. Toy, C.S. Rivers, Z. Modrusan, L.C. Amler, and M.R. Lackner Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer Cancer Res. 68 2008 5380 5389
106. S.H. Olejniczak, C.C. Stewart, K. Donohue, and M.S. Czuczman A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry Immunol. Invest. 35 2006 93 114
107. E. Paietta, O. Goloubeva, D. Neuberg, J.M. Bennett, R. Gallagher, J. Racevskis, G. Dewald, P.H. Wiernik, M.S. Tallman, and G. Eastern Cooperative Oncology A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes Cytometry B: Clin. Cytom. 59 2004 1 9
108. Z. Palyi-Krekk, M. Barok, J. Isola, M. Tammi, J. Szollosi, and P. Nagy Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer Eur. J. Cancer 43 2007 2423 2433
109. D. Papachristou, A.F. Zaki, and J.G. Fortner Chlorambucil-carrying ALG as an immunosuppressive agent in the rat Transplant. Proc. 9 1977 1059 1062
110. H.L. Perez, P.M. Cardarelli, S. Deshpande, S. Gangwar, G.M. Schroeder, G.D. Vite, and R.M. Borzilleri Antibody-drug conjugates: current status and future directions Drug Discov. Today 19 2014 869 881
111. B.H. Petersen, S.V. DeHerdt, D.W. Schneck, and T.F. Bumol The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies Cancer Res. 51 1991 2286 2290
112. G.D. Phillips, C.T. Fields, G. Li, D. Dowbenko, G. Schaefer, K. Miller, F. Andre, H.A. Burris 3rd, K.S. Albain, N. Harbeck, V. Dieras, D. Crivellari, L. Fang, E. Guardino, S.R. Olsen, L.M. Crocker, and M.X. Sliwkowski Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy Clin. Cancer Res. 20 2014 456 468
113. G.A. Pietersz, and K. Krauer Antibody-targeted drugs for the therapy of cancer J. Drug Target 2 1994 183 215
114. A.G. Polson, W.Y. Ho, and V. Ramakrishnan Investigational antibody-drug conjugates for hematological malignancies Expert Opin. Investig. Drugs 20 2011 75 85
115. D. Rabuka, J.S. Rush, G.W. deHart, P. Wu, and C.R. Bertozzi Site-specific chemical protein conjugation using genetically encoded aldehyde tags Nat. Protoc. 7 2012 1052 1067
116. L. Reslan, S. Dalle, and C. Dumontet Understanding and circumventing resistance to anticancer monoclonal antibodies MAbs 1 2009 222 229
117. A.D. Ricart Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin Clin. Cancer Res. 17 2011 6417 6427
118. A.D. Ricart, and A.W. Tolcher Technology insight: cytotoxic drug immunoconjugates for cancer therapy Nat. Clin. Pract. Oncol. 4 2007 245 255
119. M. Ritchie, L. Tchistiakova, and N. Scott Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates MAbs 5 2013 13 21
120. T. Rohrer New weapons for the oncology arsenal Chem. Rundschau 9 2008 26 28
121. T. Rohrer Considerations for the safe and effective manufacturing of antibody drug conjugates Chem. Oggi/Chem. Today 30 2012 76 79
122. D.B. Rosen, K.H. Harrington, J.A. Cordeiro, L.Y. Leung, S. Putta, N. Lacayo, G.S. Laszlo, C.J. Gudgeon, D.E. Hogge, R.E. Hawtin, A. Cesano, and R.B. Walter AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin PLOS ONE 8 2013 e53518
123. G. Saito, J.A. Swanson, and K.D. Lee Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities Adv Drug Deliv Rev 55 2003 199 215
124. R.J. Sanderson, M.A. Hering, S.F. James, M.M. Sun, S.O. Doronina, A.W. Siadak, P.D. Senter, and A.F. Wahl In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate Clin. Cancer Res. 11 2005 843 852
125. P. Sapra, A.T. Hooper, C.J. O'Donnell, and H.P. Gerber Investigational antibody drug conjugates for solid tumors Expert Opin. Investig. Drugs 20 2011 1131 1149
126. A.M. Scott, F.T. Lee, N. Tebbutt, R. Herbertson, S.S. Gill, Z. Liu, E. Skrinos, C. Murone, T.H. Saunder, B. Chappell, A.T. Papenfuss, A.M. Poon, W. Hopkins, F.E. Smyth, D. MacGregor, L.M. Cher, A.A. Jungbluth, G. Ritter, M.W. Brechbiel, R. Murphy, A.W. Burgess, E.W. Hoffman, T.G. Johns, and L.J. Old A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors Proc. Natl. Acad. Sci. U. S. A. 104 2007 4071 4076
127. A.M. Scott, J.D. Wolchok, and L.J. Old Antibody therapy of cancer Nat. Rev. Cancer 12 2012 278 287
128. P.D. Senter Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13 2009 235 244
129. P.D. Senter, and E.L. Sievers The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30 2012 631 637
130. J.R. Sierra, V. Cepero, and S. Giordano Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Mol. Cancer 9 2010 75
131. E.L. Sievers, R.A. Larson, E.A. Stadtmauer, E. Estey, B. Lowenberg, H. Dombret, C. Karanes, M. Theobald, J.M. Bennett, M.L. Sherman, M.S. Berger, C.B. Eten, M.R. Loken, J.J. van Dongen, I.D. Bernstein, and F.R. Appelbaum Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J. Clin. Oncol. 19 2001 3244 3254
132. E.L. Sievers, R.A. Larson, E.A. Stadtmauer, E. Estey, B. Lowenberg, H. Dombret, C. Karanes, M. Theobald, J.M. Bennett, M.L. Sherman, M.S. Berger, C.B. Eten, M.R. Loken, J.J. van Dongen, I.D. Bernstein, F.R. Appelbaum, and G. Mylotarg Study Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J. Clin. Oncol. 19 2001 3244 3254
133. E.L. Sievers, and P.D. Senter Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64 2013 15 29
134. Y. Singh, M. Palombo, and P.J. Sinko Recent trends in targeted anticancer prodrug and conjugate design Curr. Med. Chem. 15 2008 1802 1826
135. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
136. J.B. Stimmel, B.M. Merrill, L.F. Kuyper, C.P. Moxham, J.T. Hutchins, M.E. Fling, and F.C. Kull Jr. Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies J. Biol. Chem. 275 2000 30445 30450
137. P. Strop, S.H. Liu, M. Dorywalska, K. Delaria, R.G. Dushin, T.T. Tran, W.H. Ho, S. Farias, M.G. Casas, Y. Abdiche, D. Zhou, R. Chandrasekaran, C. Samain, C. Loo, A. Rossi, M. Rickert, S. Krimm, T. Wong, S.M. Chin, J. Yu, J. Dilley, J. Chaparro-Riggers, G.F. Filzen, C.J. O'Donnell, F. Wang, J.S. Myers, J. Pons, D.L. Shelton, and A. Rajpal Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20 2013 161 167
138. M. Sunbul, and J. Yin Site specific protein labeling by enzymatic posttranslational modification Org. Biomol. Chem. 7 2009 3361 3371
139. T. Suzawa, S. Nagamura, H. Saito, S. Ohta, N. Hanai, and M. Yamasaki Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly(ethylene glycol)-dipeptidyl linker capable of tumor specific activation Bioorg. Med. Chem. 8 2000 2175 2184
140. S.M. Swain, S.B. Kim, J. Cortes, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J.M. Ferrero, A. Schneeweiss, A. Knott, E. Clark, G. Ross, M.C. Benyunes, and J. Baselga Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol. 14 2013 461 471
141. A. Takeshita Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia Int. J. Hematol. 97 2013 703 716
142. A. Takeshita, K. Shinjo, N. Yamakage, T. Ono, I. Hirano, H. Matsui, K. Shigeno, S. Nakamura, T. Tobita, M. Maekawa, K. Ohnishi, Y. Sugimoto, H. Kiyoi, T. Naoe, and R. Ohno CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma Br. J. Haematol. 146 2009 34 43
143. A. Takeshita, N. Yamakage, K. Shinjo, T. Ono, I. Hirano, S. Nakamura, K. Shigeno, T. Tobita, M. Maekawa, H. Kiyoi, T. Naoe, K. Ohnishi, Y. Sugimoto, and R. Ohno CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells Leukemia 23 2009 1329 1336
144. X. Tan, G. Jin, J. Myers, V. Diesl, M. Follettie, M.H. Lam, S. Musto, K. Khandke, M. Charati, E. Graziani, A. Maderna, C. Subramanyam, F. Koehn, R. Dushin, K. Arndt, C.J. O'Donnell, H.P. Gerber, and F. Loganzo Tumor cells selected for resistance to an antibody-drug conjugate retain sensitivity to ADCs with modified linkers and payloads [abstract] Cancer Res. 73 2013 (Abstract 4629)
145. B.A. Teicher, and R.V. Chari Antibody conjugate therapeutics: challenges and potential Clin. Cancer Res. 17 2011 6389 6397
146. B. ten Cate, D.F. Samplonius, T. Bijma, L.F. de Leij, W. Helfrich, and E. Bremer The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells Leukemia 21 2007 248 252
147. G.M. Thurber, M.M. Schmidt, and K.D. Wittrup Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance Adv. Drug Deliv. Rev. 60 2008 1421 1434
148. A. Tsimberidou, J. Cortes, D. Thomas, G. Garcia-Manero, S. Verstovsek, S. Faderl, M. Albitar, H. Kantarjian, E. Estey, and F.J. Giles Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia Leuk. Res. 27 2003 893 897
149. T. Tsuruo Mechanisms of multidrug resistance and implications for therapy Jpn. J. Cancer Res. 79 1988 285 296
150. K. Ueda, Y. Taguchi, and M. Morishima How does P-glycoprotein recognize its substrates? Semin. Cancer Biol. 8 1997 151 159
151. B.J. Van den Eynde, and A.M. Scott D.P.J. Roitt, I.M. Roitt, Encyclopedia of Immunology 1998 Academic Press London 2424 2431
152. D.M. van der Kolk, E.G. de Vries, M. Muller, and E. Vellenga The role of drug efflux pumps in acute myeloid leukemia Leuk. Lymph. 43 2002 685 701
153. V.H. van der Velden, N. Boeckx, I. Jedema, J.G. te Marvelde, P.G. Hoogeveen, M. Boogaerts, and J.J. van Dongen High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients Leukemia 18 2004 983 988
154. V.H. van Der Velden, J.G. te Marvelde, P.G. Hoogeveen, I.D. Bernstein, A.B. Houtsmuller, M.S. Berger, and J.J. van Dongen Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells Blood 97 2001 3197 3204
155. S. Verma, D. Miles, L. Gianni, I.E. Krop, M. Welslau, J. Baselga, M. Pegram, D.Y. Oh, V. Dieras, E. Guardino, L. Fang, M.W. Lu, S. Olsen, K. Blackwell, and E.S. Group Trastuzumab emtansine for HER2-positive advanced breast cancer N. Engl. J. Med. 367 2012 1783 1791
156. R.B. Walter, B.W. Raden, M.R. Cronk, I.D. Bernstein, F.R. Appelbaum, and D.E. Banker The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin Blood 103 2004 4276 4284
157. R.B. Walter, B.W. Raden, T.C. Hong, D.A. Flowers, I.D. Bernstein, and M.L. Linenberger Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells Blood 102 2003 1466 1473
158. R.B. Walter, B.W. Raden, D.M. Kamikura, J.A. Cooper, and I.D. Bernstein Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity Blood 105 2005 1295 1302
159. A.M. Wardley, X. Pivot, F. Morales-Vasquez, L.M. Zetina, M. de Fatima Dias Gaui, D.O. Reyes, J. Jassem, C. Barton, P. Button, V. Hersberger, and A.A. Torres Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer J. Clin. Oncol. 28 2010 976 983
160. L.M. Weiner, R. Surana, and S. Wang Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 10 2010 317 327
161. H. Wildiers, S.B. Kim, A. Gonzalez-Martin, P.M. LoRusso, J.M. Ferrero, M. Smitt, R. Yu, A. Leung, and I.E. Krop T-DM1 for HER2-positive metastatic breast cancer: primary results of TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice [abstract LBA15] Eur. J. Cancer Suppl. 2013 S7 S8
162. A.M. Wu, and P.D. Senter Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 23 2005 1137 1146
163. E. Yao, W. Zhou, S.T. Lee-Hoeflich, T. Truong, P.M. Haverty, J. Eastham-Anderson, N. Lewin-Koh, B. Gunter, M. Belvin, L.J. Murray, L.S. Friedman, M.X. Sliwkowski, and K.P. Hoeflich Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab Clin. Cancer Res. 15 2009 4147 4156
164. A. Younes, N.L. Bartlett, J.P. Leonard, D.A. Kennedy, C.M. Lynch, E.L. Sievers, and A. Forero-Torres Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N. Engl. J. Med. 363 2010 1812 1821
165. T.S. Young, and P.G. Schultz Beyond the canonical 20 amino acids: expanding the genetic lexicon J. Biol. Chem. 285 2010 11039 11044
166. R.Y. Zhao, H.K. Erickson, B.A. Leece, E.E. Reid, V.S. Goldmacher, J.M. Lambert, and R.V. Chari Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer J. Med. Chem. 55 2012 766 782
167. R.Y. Zhao, S.D. Wilhelm, C. Audette, G. Jones, B.A. Leece, A.C. Lazar, V.S. Goldmacher, R. Singh, Y. Kovtun, W.C. Widdison, J.M. Lambert, and R.V. Chari Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates J. Med. Chem. 54 2011 3606 3623
168. D.C. Zhou, R. Zittoun, and J.P. Marie Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia Leukemia 9 1995 1661 1666